IP Library › Granted Patent US 12,364,683
Granted Patent B2
US 12,364,683 · App. 18/600,419 · Granted Jul 22, 2025

Non-sedating dexmedetomidine treatment regimens

Inventors: Vasukumar Kakumanu (New Haven, CT); David Christian Hanley (New Haven, CT); Frank Yocca (New Haven, CT); Chetan Dalpatbhai Lathia (New Haven, CT); Lavanya Rajachandran (New Haven, CT); Robert Risinger (New Haven, CT)
Assignee: BioXcel Therapeutics, Inc.
A61K31/4174A61K9/006A61K47/38A61P25/18A61P25/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,683
App. No.
18/600,419
Granted
Jul 22, 2025
Kind
B2
Abstract

Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Claims (24)

1. A method of treating acute agitation in an agitated human subject at risk of torsades de pointes or sudden death, comprising:

administering dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation up to a maximum dosing regimen;

wherein the maximum dosing regimen is a single dose of 120 mcg of dexmedetomidine and;

wherein the agitated human subject exhibits a maximum allowed QT prolongation of less than 7 msec.

2. The method of claim 1 , wherein the maximum allowed QT prolongation is further based on at least one risk factor for the risk of torsades de pointes or sudden death.

3. The method of claim 2 , wherein the at least one risk factor is a known QT prolongation of the agitated human subject.

4. The method of claim 2 , wherein the at least one risk factor is a history of other arrhythmias of the agitated human subject.

5. The method of claim 2 , wherein the at least one risk factor is a symptomatic bradycardia of the agitated human subject.

6. The method of claim 2 , wherein the at least one risk factor is a hypokalemia of the agitated human subject.

7. The method of claim 2 , wherein the at least one risk factor is a hypomagnesemia of the agitated human subject.

8. The method of claim 2 , wherein the at least one risk factor is additional drugs that prolong the QT interval of the agitated human subject.

9. The method of claim 3 , wherein the at least one risk factor comprises a history of other arrhythmias, a symptomatic bradycardia, hypokalemia or hypomagnesemia, and additional drugs known to prolong the QT interval of the agitated human subject.

10. A method of treating acute agitation in an agitated human subject at risk of torsades de pointes or sudden death, comprising:

administering dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation up to a maximum dosing regimen;

wherein the maximum dosing regimen is a single dose of 120 mcg of dexmedetomidine; and

wherein the agitated human subject exhibits a maximum allowed QT prolongation is of less than 6 msec.

11. The method of claim 10 , wherein the maximum allowed QT prolongation of the agitated human subject is further based on at least one risk factor for the risk of torsades de pointes or sudden death.

12. The method of claim 11 , wherein the at least one risk factor is a known QT prolongation of the agitated human subject.

13. The method of claim 11 , wherein the at least one risk factor is a history of other arrhythmias of the agitated human subject.

14. The method of claim 11 , wherein the at least one risk factor is a symptomatic bradycardia of the agitated human subject.

15. The method of claim 11 , wherein the at least one risk factor is a hypokalemia of the agitated human subject.

16. The method of claim 11 , wherein the at least one risk factor is a hypomagnesemia of the agitated human subject.

17. The method of claim 11 , wherein the at least one risk factor is additional drugs that prolong the QT interval of the agitated human subject.

18. The method of claim 12 , wherein the at least one risk factor comprises a history of other arrhythmias, a symptomatic bradycardia, hypokalemia or hypomagnesemia, and additional drugs that prolong the QT interval of the agitated human subject.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2026
From: E.Z. BIOXCEL SOLUTIONS PVT. LTD.
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 075124/0786 →
SECURITY INTEREST Recorded Sep 11, 2024
From: BIOXCEL THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 068938/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2024
From: KAKUMANU, VASUKUMAR; HANLEY, DAVID CHRISTIAN; YOCCA, FRANK; LATHIA, CHETAN DALPATBHAI; RAJACHANDRAN, LAVANYA; RISINGER, ROBERT
To: BIOXCEL THERAPEUTICS, INC.
Reel/Frame 067086/0078 →
Continuity (4)
Continuation 18526686 · Dec 1, 2023
Continuation 18189073 · Mar 23, 2023
Continuation 18153870 · Jan 12, 2023
Related Publication 20240277669A1 · Aug 22, 2024
References Cited (400)
US 4670455A · Virtanen et al. · 1987 [cited by applicant]
US 4839170A · Sarnoff et al. · 1989 [cited by applicant]
US 5395907A · Zajaczkowski · 1995 [cited by applicant]
US 5508367A · Zajaczkowski · 1996 [cited by applicant]
US 5565268A · Zajaczkowski · 1996 [cited by applicant]
US 5605911A · Olney et al. · 1997 [cited by applicant]
US 5700873A · Zajaczkowski et al. · 1997 [cited by applicant]
US 5712301A · Jaatinen et al. · 1998 [cited by applicant]
US 5726250A · Zajaczkowski · 1998 [cited by applicant]
US 5731387A · Zajaczkowski · 1998 [cited by applicant]
US 5951999A · Therriault et al. · 1999 [cited by applicant]
US 6174546B1 · Therriault et al. · 2001 [cited by applicant]
US 6200604B1 · Pather et al. · 2001 [cited by applicant]
US 6221392B1 · Khankari et al. · 2001 [cited by applicant]
US 6239228B1 · Zajaczkowski · 2001 [cited by applicant]
US 6716867B1 · Aantaa et al. · 2004 [cited by applicant]
US 6753782B2 · Power · 2004 [cited by applicant]
US 7001609B1 · Matson et al. · 2006 [cited by applicant]
US 7357891B2 · Yang et al. · 2008 [cited by applicant]
US 7425292B2 · Yang et al. · 2008 [cited by applicant]
US 7470397B2 · Meathrel et al. · 2008 [cited by applicant]
US 7579019B2 · Tapolsky et al. · 2009 [cited by applicant]
US 7630758B2 · Lapinlampi et al. · 2009 [cited by applicant]
US 7666337B2 · Yang et al. · 2010 [cited by applicant]
US 7727466B2 · Meathrel et al. · 2010 [cited by applicant]
US 7897080B2 · Yang et al. · 2011 [cited by applicant]
US 7972618B2 · Fuisz et al. · 2011 [cited by applicant]
US 8241661B1 · Fuisz et al. · 2012 [cited by applicant]
US 8242158B1 · Roychowdhury et al. · 2012 [cited by applicant]
US 8282954B2 · Bogue et al. · 2012 [cited by applicant]
US 8324260B1 · Garcia Da Rocha et al. · 2012 [cited by applicant]
US 8338470B1 · Roychowdhury et al. · 2012 [cited by applicant]
US 8364221B2 · Mannheimer et al. · 2013 [cited by applicant]
US 8414922B2 · Bryson et al. · 2013 [cited by applicant]
US 8436033B1 · Roychowdhury et al. · 2013 [cited by applicant]
US 8455527B1 · Roychowdhury et al. · 2013 [cited by applicant]
US 8568777B2 · Fuisz · 2013 [cited by applicant]
US 8617589B2 · Fuisz et al. · 2013 [cited by applicant]
US 8648106B2 · Roychowdhury et al. · 2014 [cited by applicant]
US 8663687B2 · Myers et al. · 2014 [cited by applicant]
US 8663696B2 · Myers et al. · 2014 [cited by applicant]
US 8685437B2 · Yang et al. · 2014 [cited by applicant]
US 8846074B2 · Bryson et al. · 2014 [cited by applicant]
US 8882684B2 · Halperin et al. · 2014 [cited by applicant]
US 8882703B2 · Hickle · 2014 [cited by applicant]
US 8900498B2 · Yang et al. · 2014 [cited by applicant]
US 8936825B2 · Myers et al. · 2015 [cited by applicant]
US 9073294B2 · Kumar et al. · 2015 [cited by applicant]
US 9248146B2 · Barnhart et al. · 2016 [cited by applicant]
US 9283219B2 · Bryson et al. · 2016 [cited by applicant]
US 9303918B2 · Li · 2016 [cited by applicant]
US 9320712B2 · Roychowdhury et al. · 2016 [cited by applicant]
US 9346601B2 · Bogue et al. · 2016 [cited by applicant]
US 9427412B2 · Bryson et al. · 2016 [cited by applicant]
US 9441142B2 · Malik et al. · 2016 [cited by applicant]
US 9545376B2 · Musho et al. · 2017 [cited by applicant]
US 9561191B2 · Myers et al. · 2017 [cited by applicant]
US 9572773B2 · Dormady et al. · 2017 [cited by applicant]
US 9585961B2 · Barnhart et al. · 2017 [cited by applicant]
US 9616049B2 · Roychowdhury et al. · 2017 [cited by applicant]
US 9649296B1 · Pizza · 2017 [cited by applicant]
US 9662297B2 · Musho et al. · 2017 [cited by applicant]
US 9662301B2 · Musho et al. · 2017 [cited by applicant]
US 9717796B1 · Pizza · 2017 [cited by applicant]
US 9795559B2 · Henwood et al. · 2017 [cited by applicant]
US 9814674B2 · Musho et al. · 2017 [cited by applicant]
US 9855221B2 · Myers et al. · 2018 [cited by applicant]
US 9901650B2 · Nedergaard et al. · 2018 [cited by applicant]
US 9931305B2 · Yang et al. · 2018 [cited by applicant]
US 9937122B2 · Zhu et al. · 2018 [cited by applicant]
US 9937123B2 · Barnhart et al. · 2018 [cited by applicant]
US 9993428B2 · Gerard et al. · 2018 [cited by applicant]
US 10130684B2 · Rubin et al. · 2018 [cited by applicant]
US 10130766B1 · Bibian et al. · 2018 [cited by applicant]
US 10137245B2 · Melker et al. · 2018 [cited by applicant]
US 10285953B2 · Bryson et al. · 2019 [cited by applicant]
US 10314503B2 · Prerau et al. · 2019 [cited by applicant]
US 10383574B2 · Purdon et al. · 2019 [cited by applicant]
US 10602978B2 · Purdon et al. · 2020 [cited by applicant]
US 10792246B2 · Kakumanu et al. · 2020 [cited by applicant]
US 11116723B2 · Temtsin-Krayz · 2021 [cited by applicant]
US 20020037977A1 · Feldstein et al. · 2002 [cited by applicant]
US 20030096012A1 · Besse et al. · 2003 [cited by applicant]
US 20030124191A1 · Besse et al. · 2003 [cited by applicant]
US 20030145854A1 · Hickle · 2003 [cited by applicant]
US 20030158242A1 · Kugelmann · 2003 [cited by applicant]
US 20040138312A1 · Wheeler et al. · 2004 [cited by applicant]
US 20050037055A1 · Yang et al. · 2005 [cited by applicant]
US 20050118217A1 · Barnhart et al. · 2005 [cited by applicant]
US 20050222270A1 · Olney et al. · 2005 [cited by applicant]
US 20060058590A1 · Shaw et al. · 2006 [cited by applicant]
US 20060058700A1 · Marro et al. · 2006 [cited by applicant]
US 20060069086A1 · Michalow · 2006 [cited by applicant]
US 20070281003A1 · Fuisz et al. · 2007 [cited by applicant]
US 20080026040A1 · Farr et al. · 2008 [cited by applicant]
US 20080124381A1 · Barnhart et al. · 2008 [cited by applicant]
US 20080280947A1 · Blondino et al. · 2008 [cited by applicant]
US 20080299005A1 · Meathrel et al. · 2008 [cited by applicant]
US 20080306980A1 · Brunner et al. · 2008 [cited by applicant]
US 20090076156A1 · Husain et al. · 2009 [cited by applicant]
US 20090099480A1 · Salgo et al. · 2009 [cited by applicant]
US 20090142850A1 · Meathrel et al. · 2009 [cited by applicant]
US 20090275853A1 · Sarkela · 2009 [cited by applicant]
US 20100130566A1 · Purpura et al. · 2010 [cited by applicant]
US 20100196286A1 · Armer et al. · 2010 [cited by applicant]
US 20110021588A1 · Henwood et al. · 2011 [cited by applicant]
US 20110066004A1 · Sullivan et al. · 2011 [cited by applicant]
US 20110245633A1 · Goldberg et al. · 2011 [cited by applicant]
US 20110290694A1 · Fuisz et al. · 2011 [cited by applicant]
US 20120076921A1 · Myers et al. · 2012 [cited by applicant]
US 20120100278A1 · Nowak et al. · 2012 [cited by applicant]
US 20120195955A1 · Bryson et al. · 2012 [cited by applicant]
US 20120309804A1 · Horn · 2012 [cited by applicant]
US 20120325209A1 · Quintin · 2012 [cited by applicant]
US 20120328688A1 · Fuisz et al. · 2012 [cited by applicant]
US 20130072532A1 · Henwood et al. · 2013 [cited by applicant]
US 20130095156A1 · Barnhart et al. · 2013 [cited by applicant]
US 20130096172A1 · Garcia Da Rocha et al. · 2013 [cited by applicant]
US 20130116215A1 · Coma et al. · 2013 [cited by applicant]
US 20130178465A1 · Henwood et al. · 2013 [cited by applicant]
US 20130225626A1 · Bryson et al. · 2013 [cited by applicant]
US 20140010873A1 · Tygesen et al. · 2014 [cited by applicant]
US 20140163080A1 · Horn · 2014 [cited by applicant]
US 20140203480A1 · Musho et al. · 2014 [cited by applicant]
US 20140261990A1 · Dadey et al. · 2014 [cited by applicant]
US 20140287181A1 · Malik et al. · 2014 [cited by applicant]
US 20140316217A1 · Purdon et al. · 2014 [cited by applicant]
US 20140323898A1 · Purdon et al. · 2014 [cited by applicant]
US 20140377329A1 · Bryson et al. · 2014 [cited by applicant]
US 20150098980A1 · Pongpeerapat et al. · 2015 [cited by applicant]
US 20150098981A1 · Pongpeerapat et al. · 2015 [cited by applicant]
US 20150098982A1 · Pongpeerapat et al. · 2015 [cited by applicant]
US 20150098983A1 · Pongpeerapat et al. · 2015 [cited by applicant]
US 20150098997A1 · Pongpeerapat et al. · 2015 [cited by applicant]
US 20150141772A1 · LeBoeuf et al. · 2015 [cited by applicant]
US 20150250957A1 · Albalat · 2015 [cited by applicant]
US 20150258067A1 · Kokkonen et al. · 2015 [cited by applicant]
US 20160000945A1 · Nedergaard et al. · 2016 [cited by applicant]
US 20160113885A1 · Myers et al. · 2016 [cited by applicant]
US 20160151299A1 · Bryson et al. · 2016 [cited by applicant]
US 20160310441A1 · Yamazaki et al. · 2016 [cited by applicant]
US 20160324446A1 · Prerau et al. · 2016 [cited by applicant]
US 20160338972A1 · Bryson et al. · 2016 [cited by applicant]
US 20160374588A1 · Shariff et al. · 2016 [cited by applicant]
US 20170087084A1 · Musho et al. · 2017 [cited by applicant]
US 20170087097A1 · Musho et al. · 2017 [cited by applicant]
US 20170128358A1 · Barnhart et al. · 2017 [cited by applicant]
US 20170128421A1 · Sura et al. · 2017 [cited by applicant]
US 20170165235A1 · Roychowdhury et al. · 2017 [cited by applicant]
US 20170231556A1 · Purdon et al. · 2017 [cited by applicant]
US 20170239221A1 · Harsh et al. · 2017 [cited by applicant]
US 20170246108A1 · Musho et al. · 2017 [cited by applicant]
US 20170252294A1 · Musho et al. · 2017 [cited by applicant]
US 20170273611A1 · Purdon et al. · 2017 [cited by applicant]
US 20170274174A1 · Purdon et al. · 2017 [cited by applicant]
US 20170296482A1 · Myers et al. · 2017 [cited by applicant]
US 20180055764A1 · Henwood et al. · 2018 [cited by applicant]
US 20180065767A1 · Bogue et al. · 2018 [cited by applicant]
US 20180098937A1 · Horn · 2018 [cited by applicant]
US 20180110897A1 · Bush et al. · 2018 [cited by applicant]
US 20180147201A1 · Toledano · 2018 [cited by applicant]
US 20180177797A1 · Berdahl et al. · 2018 [cited by applicant]
US 20180360736A1 · Obeid et al. · 2018 [cited by applicant]
US 20190209022A1 · Sobol et al. · 2019 [cited by applicant]
US 20190216345A1 · Scheib · 2019 [cited by applicant]
US 20190216389A1 · Scheib · 2019 [cited by applicant]
US 20190365715A1 · Nandabalan et al. · 2019 [cited by applicant]
US 20190374158A1 · Brown et al. · 2019 [cited by applicant]
US 20200000708A1 · Barnhart et al. · 2020 [cited by applicant]
US 20200000717A1 · Kakumanu et al. · 2020 [cited by applicant]
US 20200069650A1 · Korpivaara et al. · 2020 [cited by applicant]
US 20200093800A1 · Pongpeerapat et al. · 2020 [cited by applicant]
US 20200168340A1 · Park et al. · 2020 [cited by applicant]
US 20200345635A1 · Kakumanu et al. · 2020 [cited by applicant]
US 20210077388A1 · Kakumanu et al. · 2021 [cited by applicant]
US 20210267944A1 · Yocca et al. · 2021 [cited by applicant]
US 20220031663A1 · Nandabalan et al. · 2022 [cited by applicant]
US 20220110864A1 · Kakumanu et al. · 2022 [cited by applicant]
US 20220142918A1 · Kakumanu et al. · 2022 [cited by applicant]
US 20220160629A1 · Kakumanu et al. · 2022 [cited by applicant]
US 20220202373A1 · Yocca et al. · 2022 [cited by applicant]
AU 2007201370B2 · 2009 [cited by applicant]
AU 2009238370B2 · 2011 [cited by applicant]
AU 2014227693B2 · 2018 [cited by applicant]
CA 2324967A1 · 2002 [cited by applicant]
CN 101496801A · 2009 [cited by applicant]
CN 102657635A · 2012 [cited by applicant]
CN 104784174A · 2015 [cited by applicant]
CN 105287519A · 2016 [cited by applicant]
CN 106539778A · 2017 [cited by applicant]
CN 106727443A · 2017 [cited by applicant]
CN 106727524A · 2017 [cited by applicant]
CN 107137399A · 2017 [cited by applicant]
CN 107412204A · 2017 [cited by applicant]
CN 107693485A · 2018 [cited by applicant]
CN 109620802A · 2019 [cited by applicant]
CN 110893186A · 2020 [cited by applicant]
CN 111481506A · 2020 [cited by applicant]
CN 112138250A · 2020 [cited by applicant]
EP 0681601B1 · 1999 [cited by applicant]
EP 1549305B1 · 2009 [cited by applicant]
EP 1695094B1 · 2013 [cited by applicant]
EP 3326612A1 · 2018 [cited by applicant]
JP 2009526829A · 2009 [cited by applicant]
KR 101859486B1 · 2018 [cited by applicant]
KR 20190109310A · 2019 [cited by applicant]
RU 2635532C1 · 2017 [cited by applicant]
WO WO9514746A2 · 1995 [cited by applicant]
WO WO9837111A1 · 1998 [cited by applicant]
WO WO2004032913A1 · 2004 [cited by applicant]
WO WO2005032519A1 · 2005 [cited by applicant]
WO WO2005039499A2 · 2005 [cited by applicant]
WO WO2006090371A2 · 2006 [cited by applicant]
WO WO2008079721A1 · 2008 [cited by applicant]
WO WO2008091588A1 · 2008 [cited by applicant]
WO WO2009048606A1 · 2009 [cited by applicant]
WO WO2009076165A1 · 2009 [cited by applicant]
WO WO2010132882A2 · 2010 [cited by applicant]
WO WO2012009144A2 · 2012 [cited by applicant]
WO WO2012075373A2 · 2012 [cited by applicant]
WO WO2012083269A1 · 2012 [cited by applicant]
WO WO2012177326A1 · 2012 [cited by applicant]
WO WO2013090278A2 · 2013 [cited by applicant]
WO WO2013103378A1 · 2013 [cited by applicant]
WO WO2013130577A2 · 2013 [cited by applicant]
WO WO2013173317A1 · 2013 [cited by applicant]
WO WO2014130777A1 · 2014 [cited by applicant]
WO WO2014153489A1 · 2014 [cited by applicant]
WO WO2014176444A1 · 2014 [cited by applicant]
WO WO2013090278A3 · 2014 [cited by applicant]
WO WO2015054058A1 · 2015 [cited by applicant]
WO WO2015054059A2 · 2015 [cited by applicant]
WO WO2015054061A1 · 2015 [cited by applicant]
WO WO2015054063A1 · 2015 [cited by applicant]
WO WO2016061413A1 · 2016 [cited by applicant]
WO WO2016061554A1 · 2016 [cited by applicant]
WO WO2016075365A1 · 2016 [cited by applicant]
WO WO2016089997A1 · 2016 [cited by applicant]
WO WO2017117627A1 · 2017 [cited by applicant]
WO WO2018072015A1 · 2018 [cited by applicant]
WO WO2018086498A1 · 2018 [cited by applicant]
WO WO2018109272A1 · 2018 [cited by applicant]
WO WO2018116202A1 · 2018 [cited by applicant]
WO WO2018126182A1 · 2018 [cited by applicant]
WO WO2019036253A1 · 2019 [cited by applicant]
WO WO2019070929A1 · 2019 [cited by applicant]
WO WO2019158810A1 · 2019 [cited by applicant]
WO WO2020006073A1 · 2020 [cited by applicant]
WO WO2020006092A1 · 2020 [cited by applicant]
WO WO2020006119A1 · 2020 [cited by applicant]
WO WO2020259440A1 · 2020 [cited by applicant]
WO WO2021016112A2 · 2021 [cited by applicant]
WO WO2021055595A1 · 2021 [cited by applicant]
Aantaa, et al., “Intramuscular dexmedetomidine, a novel alpha2-adrenoceptor agonist, as premedication for minor gynaecological surgery.” Acta Anaesthesiol Scand 35(4): 283-288 (1991). [cited by applicant]
Abdelaziz, et al., “Effect of intranasal dexmedetomidine or intranasal midazolam on prevention of emergence agitation in pediatric strabismus surgery: A randomized controlled study.” Egyptian Journal of Anaesthesia 32: … [cited by applicant]
Abdel-Ghaffar et al., “Oral trans-mucosal dexmedetomidine for controlling of emergence agitation in children undergoing tonsillectomy: a randomized controlled trial,” Rev Bras Anestesiol 69(5):469-476 (2019). [cited by applicant]
Abdelmageed, et al., “Intramuscular dexmedetomidine for prevention of shivering after general anesthesia in patients undergoing arthroscopic anterior cruciate ligament reconstruction.” Ain-Shams Journal of Anesthesiolog… [cited by applicant]
Adami, et al., “Combinations of dexmedetomidine and alfaxalone with butorphanol in cats: application of an innovative stepwise optimization method to identify optimal clinical doses for intramuscular anaesthesia.” J Fel… [cited by applicant]
Ahmad, et al., “Effects of Midazolam or Midazolam-Fentanyl on Sedation and Analgesia Produced by Intramuscular Dexmedetomidine in Dogs.” Asian Journal of Animal Sciences 5(5):302-316 (2011). [cited by applicant]
Aho, et al., “Intramuscularly administered dexmedetomidine attenuates hemodynamic and stress hormone responses to gynecologic laparoscopy.” Anesth Analg 75(6):932-939 (1992). [cited by applicant]
Aich, et al., “A Comparison of Intranasal Dexmedetomidine and Intranasal Midazolam for Premedication in Children Undergoing Elective Surgeries.” International Journal of Science and Research (IJSR) 5(7):1730-1737 (2016). [cited by applicant]
Akin, et al., “Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia.” Pediatric Anesthesia 22 (9): 871-876 (2012). [cited by applicant]
Albertson et al., “Is It Prime Time for Alpha2-Adrenocepter Agonists in the Treatment of Withdrawal Syndromes?,” J. Med. Toxicol 10:369-381 (2014). [cited by applicant]
Ali and Abdellatif, “Prevention of sevoflurane related emergence agitation in children undergoing adenotonsillectomy: A comparison of dexmedetomidine and propofol.” Saudi J Anaesth. 7(3): 296-300, 7 pages (2013). [cited by applicant]
Ambi, et al., “Intranasal dexmedetomidine for paediatric sedation for diagnostic magnetic resonance imaging studies.” Indian J Anaesth 56(6): 587-588 (2012). [cited by applicant]
Ansah, et al., “Comparison of three doses of dexmedetomidine with medetomidine in cats following intramuscular administration.” Veterinary Pharmacology and Therapeutics 21(5):380-387 (1998). [cited by applicant]
Antonino and Junior, “Effectiveness Of Intramuscular Dexmedetomidine And Methadone In Combination To Intratesticular Lidodaine For Orquiectomy In Dogs—Preliminary Study.” Investigao vol. 16, No. 7. Abstract, 2 pages (20… [cited by applicant]
Anttila, et al., “Bioavailability of dexmedetomidine after extravascular doses in healthy subjects.” British Journal of Clinical Pharmacology 56(6): 691-693 (2003). [cited by applicant]
Anusua, et al., “Efficacy of Dexmedetomidine in Reducing Emergence Agitation After Sevoflurane Anaesthesia in Indian Paediatric Population.” International Journal of Scientific Research 4(7): ISSN No. 2277-8179, pp. 458… [cited by applicant]
Anzctr Clinical Trial ID: ACTRN12616001522404, Does ketamine improve the quality of sedation of intranasal dexmedetomidine premedication in children. Fujian Provincial Hospital, Date Registered Nov. 4, 2016, Date Last U… [cited by applicant]
Aravindhanthan et al., “Sub lingual spray: a new technology oriented formulation with multiple benefits,” International Journal of Research in Pharmaceutical Sciences 10(4):2875-2885 (2019). [cited by applicant]
Assad, et al., “Comparative study between prophylactic single dose of fentanyl and dexmedetomidine in the management of agitation after sevoflurane anesthesia in children.” Egyptian Journal of Anaesthesia 27(1):31-37 (2… [cited by applicant]
Aungst, et al., “Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter.” Journal of Pharmacology and Experimental Therapeutics 244(1):23-27… [cited by applicant]
Ayeko and Mohamed, “Prevention and treatment of sevoflurane emergence agitation and delirium in children with dexmedetomidine.” Saudi J Anaesth 8(4):570-571 (2014). [cited by applicant]
Baddigam et al., “Dexmedetomidine in the Treatment of Withdrawal Syndromes in Cardiothoracic Surgery Patients,” J. Intensive Care Med., 20(2):118-123 (2005). [cited by applicant]
Bajwa et al., “Dexmedetomidine: An Adjuvant Making Large Inroads into Clinical Practice,” Annals of Medical and Health Sciences Research, 3(4):475-483 (Oct.-Dec. 2013). [cited by applicant]
Bakri, et al., “Comparison of dexmedetomidine or ondansetron with haloperidol for treatment of postoperative delirium in trauma patients admitted to intensive care unit: randomized controlled trial.” Anaesth Pain & Inte… [cited by applicant]
Barends et al., “Intranasal dexmedetomidine in elderly subjects with or without beta blockade: a randomised double-blind single-ascending-dose cohort study,” British Journal of Anaesthesia 124(4):411-419 (2020). [cited by applicant]
Bartlett et al., “Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine,” AAPS Pharm Sci Tech 13(4):1110-1115 (Dec. 2012). [cited by applicant]
Behrle, et al., “Intranasal Dexmedetomidine as a Sedative for Pediatric Procedural Sedation.” J Pediatr Pharmacol Ther (2017); 22 (1): 4-8. [cited by applicant]
Belgrade et al., “Dexmedetomidine Infusion for the Management of Opioid-Induced Hyperalgesia,” Pain Medicine, 2010; 11 :1819-1826. [cited by applicant]
Belkin et al., “Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder,” Drugs in Context 2015; 4: 212286, 5 pages. [cited by applicant]
Bergese et al., “A Phase IIIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine for Sedation During Awake Fiberoptic Intubation,” American Journal of … [cited by applicant]
Bhardwaj, et al., “Abstract PR227: Comparison of Nasal Dexmedetomidine with Oral Midazolam for Premedication in Children Effect on Psychomotor Recovery.” Anesthesia & Analgesia (2016); 123 (3S_Suppl): p. 288. [cited by applicant]
Bhat, et al., “Comparison of intranasal dexmedetomidine and dexmedetomidine-ketamine for premedication in pediatrics patients: A randomized double-blind study.” Anesth Essays Res. (2016); 10 (2): 349-355. [cited by applicant]
Bienvenu et al., “Treatment of four psychiatric emergencies in the intensive care unit,” Critical Care Medicine (2012) 40(9):2662-2670. [cited by applicant]
Biermann, et al., “Sedative, cardiovascular, haematologic and biochemical effects of four different drug combinations administered intramuscularly in cats.” Veterinary Anaesthesia and Analgesia (2012); 39 (2): 137-150. [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices,” Sep. 18, 2019, 3 pages, retrieved from: https://www… [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia,” Jan. 7, 2020, 3 pages, retrieved from https:/… [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2018 Results—Earnings Call Transcript,” Seeking Alpha, Aug. 12, 2018, 13 pages, retrieved from: https://seekingalpha.com/article/41981… [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation,” Globe Newswire, Oct. 30, 2018, 2 pages, retrieved from: https://www.globene… [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development,” Globe Newswire, Nov. 14, 2018, 3 pages, retrieved from: … [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update,” Globe Newswire, Aug. 8, 2018, 3 pages, retrieved from: https://ir.bioxceltherapeutics.com/pr… [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update,” Globe Newswire, Nov. 9, 2018, 3 pages, retrieved from: https://ir.bioxceltherapeutics.com/pre… [cited by applicant]
BioXcel Therapeutics, Inc., “BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update,” Globe Newswire, Aug. 2, 2018, 2 pages, retrieved from: https://ir.bioxceltherapeutics.com/press-relea… [cited by applicant]
BioXcel Therapeutics, Inc., “Next Wave of Medicines Utilizing AI,” Jun. 2020, 30 pages, retrieved from https://dlio3yog0oux5.cloudfront.neU_ec77451d0911d660fb193909a0alba0e/bioxceltherapeutics/db/445/3421/pdf/BioXcel+Th… [cited by applicant]
BioXcel Therapeutics, Inc., United States Securities and Exchange Commission, Form 10-K, Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, For the year ended Dec. 31, 2019, 135 pages. [cited by applicant]
Bonanno, et al., “Effectiveness of preoperative intranasal dexmedetomidine compared with oral midazolam for the prevention of emergence delirium in pediatric patients undergoing general anesthesia: a systematic review p… [cited by applicant]
Bond, et al., “Dexmedetomidine Nasal Sedation Produces More Oculocardiac Reflex During Strabismus Surgery.” Journal of Pediatric Ophthalmology and Strabismus (2016);53(5):318. [cited by applicant]
Boriosi et al., “Safety and Efficacy of Buccal Dexmedetomidine for MRI Sedation in School-Aged Children,” Hospital Pediatrics, May 2019, vol. 9, Issue 5, pp. 348-354. [cited by applicant]
Boyer, Jeanne, “Calming patient agitation with dexmedetomidine.” Nursing Critical Care (2010); 5 (1): 30-34. [cited by applicant]
Bryson E.O., et al., “Treatment-Resistant Postictal Agitation After Electroconvulsive Therapy (ECT) Controlled with Dexmedetomidine,” The Journal of ECT, 2013, 29(2):e18. [cited by applicant]
Candiotti et al., “Monitored Anesthesia Care with Dexmedetomidine: A Prospective, Randomized, Double-Blind, Multicenter Trial,” Anesth Analg 2010;110(1):47-56. [cited by applicant]
Canfran, et al., “Comparison of sedation scores and propofol induction doses in dogs after intramuscular administration of dexmedetomidine alone or in combination with methadone, midazolam, or methadone plus midazolam.”… [cited by applicant]
Carrasco et al., “Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial,” Critical Care Medicine, 2016, 44:1295-1306, 12 pages. [cited by applicant]
Carter, et al., “Onset and quality of sedation after intramuscular administration of dexmedetomidine and hydromorphone in various muscle groups in dogs.” Journal of the American Veterinary Medical Association (2013); 24… [cited by applicant]
Center for Drug Evaluation and Research, Application No. 21-038, Medical Review(s), Drug Name: Precedex (dexmedetomidine HCI injection), Dec. 18, 1998, 183 pages. [cited by applicant]
Center for Drug Evaluation and Research, Application No. 21-038, Pharmacology Review(s), Drug Name: Precedex (dexmedetomidine HCI injection), Dec. 18, 1998, 184 pages. [cited by applicant]
Changlu et al., “Determination of Effective Dosage in Intranasal Dexmedetomidine Sedation for MRI Scanning with Modified Dixon's Up-and-Down Method in Children,” China Pharmaceuticals, (2015), 24(22), 22-24, with Englis… [cited by applicant]
Chao and Zhong, “Effects of preoperative intranasal Dexmedetomidine for the bispectral index and median effective concentration of Sevoflurane in children with abdominal surgery by inhalation anesthesia of Sevoflurane.”… [cited by applicant]
Chen et al., “Dexmedetomidine alleviated isoflurane-induced neurotoxicity in aged rats,” Int J Clin Exp Med 2018;11(4):3686-3692. [cited by applicant]
Chen, et al., “Effect of dexmedetomidine on emergence agitation after oral and maxillofacial surgery.” Shanghai Journal of Stomatology (2013); 22(6): 698-701 [with English AbstracUSummary]. [cited by applicant]
Chen et al., “Protective role of dexmedetomidine in unmethylated CpG-induced inflammation responses in BV2 microglia cells,” Folia Neuropathol 2016; 54 (4): 382-391. [cited by applicant]
Cheon and Tkachenko, “Use of dexmedetomidine for prevention of post-operative agitation in a 14 year-old male with Angelman's Syndrome.” University of Chicago, Chicago, IL (2014); 1 page. [cited by applicant]
Cheung, et al., “Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia.” British Journal of Anaesthesia (2011); 107 (3): 430-437. [cited by applicant]
Cheung, et al., “Evaluation of the Analgesic Efficacy of Local Dexmedetomidine Application,” Clin J Pain, Jun. 2011, vol. 27, No. 5, pp. 337-382. [cited by applicant]
Cheung, et al., “Intranasal dexmedetomidine in combination with patientcontrolled sedation during upper gastrointestinal endoscopy: a randomised trial.” Acta Anestheologica Scandinavica (2015); 59 (2): 215-223. [cited by applicant]
Chokroverty, S., “Overview of sleep & sleep disorders,” Indian J Med Res 131, Feb. 2010, pp. 126-140. [cited by applicant]
Chowdhury et al., “General intensive care for patients with traumatic brain injury: An update,” Saudi Journal of Anaesthesia, 2014, vol. 8, Issue 2, pp. 256-263. [cited by applicant]
Christiansen, et al., “Sedation of red porgy ( [cited by applicant]
Cimen, et al., “Comparison of buccal and nasal dexmedetomidine premedication for pediatric patients.” Paediatr Anaesth. (2013); 23(2): 134-138. [cited by applicant]
Citalopram/opiate alkaloids Serotonin syndrome, treated with dexmedetomidine: case report, Reactions Weekly, Nov. 2015, vol. 1579, Issue 1, p. 117. [cited by applicant]
Clinical Trial Registration No. ChiCTR-IOR-17012415, “Effect of nasal dexmedetomidine on the prevention of emergence agitation in children undergoing day surgery with desoflurane anesthesia.” Guangzhou Women and Childre… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00417664, Is Dexmedetomidine Associated With a Lower Incidence of Postoperative Delirium When Compared to Propofol or Midazolam in Cardiac Surgery Patients, First Posted—Jan. 4, 2007, L… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02836431, Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children, First Posted—Jul. 19, 2016, Last Update Posted—Jul. 30, 2018, retrieved from https://clinicaltri… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02955732, Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients (PINDEX), First Posted Nov. 4, 2016, Last Update Posted—Sep. 12, 2018, retrieved f… [cited by applicant]
ClinicalTrials.gov Identifier: NCT03668951, Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children (DexPK), First Posted—Sep. 13, 2018, Last Update Posted—May 18, 2021, retrieved from h… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00095251, MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)—Agonist to Determine Delirium Rates, Efficacy of Sedation, An… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00351299, Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium, Jul. 12, 2006, Last Update Posted—Jun. 9, 2017, retrieved from https://… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00455143, Cognitive Protection—Dexmedetomidine and Cognitive Reserve, First Posted—Apr. 3, 2007, Last Update Posted—Jul. 17, 2019, retrieved from https://clinicaltrials.gov/ct2/show/NCT… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00460473, A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery, First Posted—Apr. 16, 2007, Last Update Posted—Jul.… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00464763, A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Heart Surgery, First Posted—Apr. 24, 2007, Last Update Posted—Mar. 21, 2017, ret… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00468052, Decrease Emergence Agitation and Provide Pain Relief for Children Undergoing Tonsillectomy & Adenoidectomy, First Posted—May 1, 2007, Last Update Posted—Dec. 5, 2016, retrieve… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00505804, A Comparison of Dexmedetomidine and Haloperidol in Patients With Intensive Care Unit (ICU)-Associated Agitation and Delirium (Dex), First Posted—Jul. 25, 2007, Last Update Pos… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00561678, Perioperative Cognitive Function—Dexmedetomidine and Cognitive Reserve, First Posted—Nov. 21, 2007, Last Update Posted—Apr. 23, 2018, retrieved from https://clinicaltrials.gov… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00654329, Dexmedetomidine vs Fentanyl for BMT (DexBMT). Children's Research Institute, First Posted Apr. 8, 2018, Results First Posted Apr. 25, 2011, Last Update Posted Apr. 25, 2011, S… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00778063, Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients (PED-DEX). Ochsner Health System, First Posted Oct. 23, 2008, Last Update Posted Mar. 15, 201… [cited by applicant]
ClinicalTrials.gov Identifier: NCT00837187, Bioavailability of Dexmedetomidine After Intranasal Administration (INDEX). University of Turku, First Posted Feb. 5, 2009, Last Update Posted Jan. 13, 2010, Study Start Date … [cited by applicant]
ClinicalTrials.gov Identifier: NCT00857727, Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children (DexPeds), First Posted—Mar. 9, 2009, Last Update Posted—Nov. 27, 2018, retrieved from https://clinica… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01065701, Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children. The University of Hong Kong, First Posted Feb. 9, 2010, Last Update Posted Oct. 26, 2017, S… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01132794, A Study to Assess the Analgesia and Sedation Using Intranasal Dexmedetomidine in Third Molar Surgery Under Local Anaesthesia. The University of Hong Kong, First Posted May 28,… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01140529, Dexmedetomidine for the Treatment of Delirium After Heart Surgery (DexinDelir), First Posted—Jun. 9, 2010, Last Update Posted—Nov. 1, 2016, retrieved from https://clinicaltria… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01151865, Dexmedetomidine to Lessen Intensive Care Unit (ICU) Agitation (DahLIA), First Posted—Jun. 29, 2010, Last Update Posted—Jan. 21, 2015, retrieved from https://clinicaltrials.gov… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01188551, Dexmedetomidine Versus Fentanyl Following Pressure Equalization Tube Placement. Nationwide Children's Hospital, First Posted Aug. 25, 2010, Last Update Posted Apr. 1, 2014, St… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01255904, A Trial Of Oral Chloral Hydrate Versus Intranasal Dexmedetomidine For Sedated Abr Exams. Baylor College of Medicine, First Posted Dec. 8, 2010, Last Update Posted May 16, 2016… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01283412, Dexmedetomidine on Postoperative Delirium and Quality of Recovery in Geriatric Patients, First Posted - —Jan. 26, 2011, Last Update Posted—Nov. 20, 2013, retrieved from https:… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01353378, Use of Dexmedetomidine in Children Undergoing Oral Maxillofacial Surgery to Decrease Emergence Delirium, First Posted—May 13, 2011, Last Update Posted—May 5, 2017, retrieved f… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01362205, Dexmedetomidine (Precedex) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD), First Posted—May 30, 2011, Last Update Posted—Nov. 6, 2017, retr… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01374737, ED50 of Dexmedetomidine to Prevent Emergence Agitation in Children, First Posted—Jun. 16, 2011, Last Update Posted—Jun. 16, 2011, downloaded Feb. 11, 2018 https://clinicaltria… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01378741, Reducing Delirium After Cardiac Surgery: A Multifaceted Approach Of Perioperative Care, First Posted—Jun. 22, 2011, Last Update Posted—Apr. 21, 2015, retrieved from https://cl… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01512355, The Effect of Dexmedetomidine on Decreasing Emergence Agitation and Delirium in Pediatric Patients Undergoing Strabismus Surgery, First Posted—Jan. 19, 2012, Last Update Poste… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01513772, The Effect of Dexmedetomidine on the Emergence Agitation in Nasal Surgery, First Posted—Jan. 20, 2012, Last Update Posted—Aug. 9, 2012, retrieved from https://clinicaltrials.g… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01517438, Effects of Serotonin Inhibitors on Patient-controlled Analgesia Related Nausea and Vomiting, First Posted—Jan. 25, 2012, Last Update Posted—Jan. 25, 2012, retrieved from https… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01517932, Effects of Dexmedetomidine on Stress Response and Postoperative Analgesia, First Posted—Jan. 25, 2012, Last Update Posted—Mar. 20, 2013, retrieved from https://clinicaltrials.… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01524367, Effect of Single-dose Dexmedetomidine on Emergence Excitement in Adults With Nasotracheal Intubation After Orthognathic Surgery, First Posted—Feb. 2, 2012, Last Update Posted—… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01528891, Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation, First Posted—Feb. 8, 2012, Last Update Posted—Jan. 20, 2016, downloaded Feb. 11, 2018 https://clinicaltri… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01528891, Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation, First Posted—Feb. 8, 2012, Last Update Posted—Mar. 8, 2018, retrieved from https://clinicaltrials.gov/ct2… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01535287, The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia. First Posted—Feb. 17, 2012, … [cited by applicant]
ClinicalTrials.gov Identifier: NCT01535287, The Effect of Intramuscular Dexmedetomidine on Emergence Agitation in Children Undergoing With or Without Tube Insertion Under General Anesthesia. First Posted—Feb. 17, 2012, … [cited by applicant]
ClinicalTrials.gov Identifier: NCT01578161, The Effect of Dexmedetomidine on Emergence Agitation in Children Undergoing a Surgery Under Desflurane Anesthesia, First Posted—Apr. 16, 2012, Last Update Posted—Apr. 16, 2012… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01691001, Effect of Dexmedetomidine on Sevoflurane Requirements and Emergence Agitation in Children Undergoing Ambulatory Surgery, First Posted—Sep. 24, 2012, Last Update Posted—Sep. 24… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01739933, The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure (MENDS2), First Pos… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01791296, Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients? (SKY-DEX), First Posted—Feb. 13, 2013, Last Update Posted—Mar. 17, 2017, retrieved from https:/… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01887184, Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy. The University of Hong Kong, First Posted Jun. 26, 2013, Last Update Posted Oct. 28, 2014, Study… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01895023, Effects of Dexmedetomidine Premedication on Emergence Agitation After Strabismus Surgery in Children. Yao Yusheng, First Posted Jul. 10, 2013, Last Update Posted Jan. 6, 2015,… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01900405, Intranasal Dexmedetomidine Sedation for Pediatric CT Imaging. University of Sao Paulo, First Posted Jul. 16, 2013, Last Update Posted Jul. 16, 2013, Study Start Date Apr. 2013… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01901588, Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery, First Posted—Mar. 8, 2016, Last Update Posted—Last Upd… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01904760, Dexmedetomidine to Prevent Agitation After Free Flap Surgery, First Posted—Jul. 22, 2013, Last Update Posted—Nov. 13, 2014, retrieved from https://clinicaltrials.gov/ct2/show/… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01934049, Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty, First Posted—Sep. 4, 2013, Last Update Posted—Sep. 10, 2013, retrieved from https://clinicaltrials… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01937611, Intramuscular Dexmedetomidine as Premedication. First Posted—Sep. 9, 2013, Last Update Posted—Sep. 9, 2013, Study Start Date—Mar. 2013, Estimated Study Completion Date—Oct. 20… [cited by applicant]
ClinicalTrials.gov Identifier: NCT01966315, The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit, First Posted—Oct. 21, 2013, Last Update Posted—Apr. 23, 2019, retrieved from https://clin… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02007798, Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia, First Posted—Dec. 11, 2013, Last Update Posted—Jan. 14, 2014… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02072083, Intranasal Dexmedetomidine vs Midazolam-ketamine Combination for Premedication of Pediatric Patients. TC Erciyes University, First Posted Feb. 26, 2014, Last Update Posted Apr… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02077712, Intranasal Dexmedetomidine Sedation for Ophthalmic Examinations in Children (DEX-EYE). Sun Yat-sen University, First Posted Mar. 4, 2014, Last Update Posted May 3, 2016, Study… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02080169, Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients, First Posted—Mar. 6, 2014, Last Update Posted—Mar. 6, 2014, retrieved from https:/… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02096068, Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Abdominal Surgery (Neuprodex), First Posted—Mar. 26, 2014, Last Update Posted—Aug. 22, 2018, re… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02104297, Effect of Deksmedetomidine and Remifentanil in Extubation Agitation (EA), First Posted—Apr. 4, 2014, Last Update Posted—Apr. 4, 2014, retrieved from https://clinicaltrials.gov… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02108171, Intranasal Dexmedetomidine Premedication. Guangzhou First People's Hospital, First Posted Apr. 9, 2014, Last Update Posted Mar. 14, 2016, Study Start Date Mar. 2014, https://c… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02117726, Impact of Various Sedation Regimens on the Incidence of Delirium, First Posted—Apr. 21, 2014, Last Update Posted—Jul. 16, 2014, retrieved from https://clinicaltrials.gov/ct2/s… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02168439, Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair. University of Pittsburgh, Results First Posted Mar. 10, 2017, Last Updat… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02169336, Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy. Recro Pharma, Inc., First Posted Jun. 23, 2014, Last Update Pos… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02169843, Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS), First Posted—Jun. 23, 2014, Last Update Posted—Jun. 23, 2014, retrieved from https://clini… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02211118, Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD. Dayton VA Medical Center, First Posted Aug. 7, 2014, Last Update Posted Feb. 8, 2017, Study St… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02222636, The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children. Xijing Hospital, First Posted Aug. 21, 2014, Last Update Posted Aug. 21, 2014, Study S… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02225210, Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients, First Posted—Aug. 26, 2014, Last Update Posted—Aug. 26, 2014, retri… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02239445, Intranasal Dexmedetomidine VS Oral Chloral Hydrate for Rescue Sedation During Magnetic Resonance Imaging. Guangzhou Women and Children's Medical Center, First Posted Sep. 12, … [cited by applicant]
ClinicalTrials.gov Identifier: NCT02245256, Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients, First Posted—Sep. 19, 2014, Last Update Posted—Jan. 25, 2018, retrieved from https://cli… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02250703, Intranasal Dexmedetomidine Premedication in Children. Results First Posted Jul. 7, 2017, Last Update Posted Jul. 7, 2017, Study Start Date Sep. 2014, downloaded https://clinic… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02253199, The Effect of Age on the Median Effective Dose (ED50) of Intranasal Dexmedetomidine for Rescue Sedation Following Failed Sedation With Oral Chloral Hydrate During Magnetic Res… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02267538, Dexmedetomidine and Delirium in Patients After Cardiac Surgery, First Posted—Feb. 2, 2018, Last Update Posted—Mar. 5, 2018, retrieved from https://clinicaltrials.gov/ct2/show/… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02275182, Impact of Dexmedetomidine on the Post-Operative Cognition Dysfunction(POCD) in Geriatric Patients, First Posted—Oct. 27, 2014, Last Update Posted—Apr. 25, 2018, retrieved from… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02284243, Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery. Recro Pharma, Inc., First Posted Nov. 5, 2014, Last Upd… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02299232, Dexmedetomidine in Children for Magnetic Resonance Imaging (MRI) Sedation (DEX). Sisli Hamidiye Etfal Training and Research Hospital, First Posted Nov. 24, 2014, Last Update P… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02366299, Comparison of Dexmedetomidine and Propofol on the Delirium and Neuroinflammation in Patients With SIRS, First Posted—Feb. 19, 2015, Last Update Posted—Feb. 19, 2015, retrieved… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02394418, Effect of Sevoflurane, Propofol and Dexmedetomidine on Delirium & Neuroinflammation in Mechanically Ventilated Patients, First Posted—Mar. 20, 2015, Last Update Posted—Jul. 5,… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02412150, Effect of Dexmedetomidine After Thyroidectomy, First Posted—Apr. 9, 2015, Last Update Posted—Mar. 6, 2019, retrieved from https://clinicaltrials.gov/ct2/show/NCT02412150, 4 pa… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02459509, A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children. The University of Hong Kong, First Posted Jun. 2, 2015, Last Update Posted Apr. 18, 2016… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02509949, Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients, First Posted—Jul. 28, 2015, Last Update Posted—Jun. 12, 2018, retrieved from… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02528513, Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine in Mechanically Ventilated Patients, First Posted—Aug. 19, 2015, Last Update Posted—Apr. 28, 2… [cited by applicant]
ClinicalTrials.gov Identifier: NCT02544906, Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation (Agitation), First Posted—Sep. 9, 2015, Last Update… [cited by applicant]